March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

DBV expects delay for peanut allergy product
DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said the Aug. 5 PDUFA date for its peanut allergy therapy may be extended as FDA has raised questions on the long-term efficacy of Viaskin and its patch-site adhesion. FDA canceled the advisory committee meeting scheduled for May 15 to discuss the BLA and may require an additional data

Read the full 601 word article

How to gain access

Continue reading with a
two-week free trial.